.svg){kind=small}
Jul-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Canna Clinicals is stocked at 12 licensed dispensaries across New York, with the deepest coverage in New York, Bellport, Canandaigua, Deer Park, and Farmingville. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Canna Clinicals concentrated 82.48% of July 2026 sales in Tincture & Sublingual, where category sales rose 19.08% year over year and 31.10% month over month, while Capsules held 7.70% share with a -22.29% year-over-year decline but a 10.71% month-over-month lift. Topical accounted for 9.82% share with no year-over-year or month-over-month markers reported, and the brand’s overall average price fell 33.20% year over year to $33.62 even as total brand sales grew 26.30% year over year. The pattern implies deliberate volume-led expansion anchored in Tincture & Sublingual and selective stabilization in Capsules, with price compression used to widen reach without diluting the category focus.
Within New York Tincture & Sublingual, Canna Clinicals sat at rank 7 in July 2026, pairing that position with an 82.48% mix concentration and a 31.10% month-over-month surge in its lead category. Combined with 143.17% sales growth over 24 months and a 33.20% year-over-year decrease in average price, the brand is trading higher price points for share velocity specifically where it competes, while maintaining a narrow second-tier presence in Capsules at 7.70% share and a measured 10.71% month-over-month uptick. The implication is a price-to-penetration strategy to consolidate rank in its core category and use small adjacent bets to hedge without distracting from the Tincture & Sublingual growth engine.
Competitive Landscape
Canna Clinicals sits at rank #7 in New York Tincture & Sublingual for July 2026, improving 1 position from #8 year over year and climbing 3 spots from #10 in April 2026, while still trailing its peak at #6 from July 2024; meanwhile, Ayrloom held #1 with a -1.9% year-over-year sales change and OMO - Open Minded Organics moved up from #6 to #5 despite a -24.7% sales decline, indicating that Canna Clinicals’ upward rank drift amid top-tier softness signals share consolidation opportunities if the brand converts its 3-rank recovery since April 2026 into sustained gains beyond #6.
Notable Products
CBD/THC/CBG1:1:1 Relief Complex Capsules 20-Pack (100mg CBD, 100mg THC, 100mg CBG) cratered by -87.38% month over month and slid to rank 6, while CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml) rose 29.24% to hold rank 1. CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) jumped 42.64% to rank 2, and CBD/CBN/THC Sleep Tincture (300mg CBD, 300mg CBN, 150mg THC) climbed 43.01% to rank 4, meaning three of the top five are Tincture & Sublingual SKUs. With tinctures advancing 29.24%–43.01% and capsules splitting between +24.63% at rank 3 and -87.38% at rank 6, the mix points to prioritizing high-potency tinctures over experimental multi-cannabinoid capsules as the commercial direction for July 2026.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
